ReviewSmall methods2024
Leveraging the Photofunctions of Transition Metal Complexes for the Design of Innovative Phototherapeutics.
Review in Small methods, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Metal-Based Photosensitizers as Emerging Antibacterial Agents for Infected Wound Healing.ChemMedChem · 2026Review
- Coumarin and Curcumin-Metal Complexes as Next-Generation Photosensitizers in Cancer Photodynamic Therapy.International journal of molecular sciences · 2026Review
- Exploring chemical space for iridium(iii) complexes: a direct-to-biology (D2B) approach to identifying anticancer and antibacterial agents.Chemical science · 2026Article
- Copper(I) photosensitisers for antimicrobial photodynamic therapy: from solution studies to silica-immobilised composite materials.Dalton transactions (Cambridge, England : 2003) · 2026Article
- Ru-Based Photocaged Kinase Inhibitors Operative under Deep-Red Light Irradiation.Journal of the American Chemical Society · 2026Article
- Erlotinib-conjugated iridium(III) complexes for EGFR-mediated photodynamic therapy of cancer.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Enzyme-Responsive Chemiluminescent Probes Assembled with Iridium(III) Photosensitizers via Host-Guest Chemistry for Chemiluminescence-Induced Photodynamic Therapy.Journal of the American Chemical Society · 2026Article
- Mitochondria-targeting cyclometallated rhodium(iii) complexes appended with two rhodamine units as Type I photosensitisers for bioimaging and photocytotoxicity applications by inducing pyroptosis.Chemical science · 2026Article
- Novel 2-(2'-Benzothiazolyl)-benzimidazole-Based Iridium(III) Photocatalysts Exhibit Antiproliferative Effects in 2D and 3D Cancer Cells to Bypass Hypoxia-Induced Resistance.Journal of medicinal chemistry · 2026Article
- Advances in pH-Sensitive Luminescent Transition Metal Complexes for Theranostic Applications.Chemistry, an Asian journal · 2026Review
- Metal-based nanomaterials for cancer phototherapy: current advancements and translational challenges.Frontiers in pharmacology · 2026Review
- Current Understanding of Bovine Ketosis: From Molecular Basis to Farm-Level Management.Animals : an open access journal from MDPI · 2025Review
- Ultrasound-activatable transition metal complexes to potentiate sonodynamic therapy.Chemical science · 2025Review
- Lysosome as a Chemical Reactor.International journal of molecular sciences · 2025Review
- Rhodamine-functionalised rhodium(iii) complexes: dual role as bioimaging agents and controllable reactive oxygen species photosensitisers for photocytotoxicity applications.Chemical science · 2025Article
- Brightening New Horizons: Luminescent Transition Metal Complexes in Optical Imaging and Theranostic Applications.ACS central science · 2025Review
- Luminescent Cyclometalated Iridium(III) Polypyridine Complexes Modified with a Dendritic Guanidinium Moiety as Molecular Glues for Combined Chemo-Photodynamic Therapy.Inorganic chemistry · 2025Article
- Recent advances in metal-organic frameworks for therapeutic applications in periodontitis.Frontiers in medicine · 2025Review
- Leveraging the Photofunctions of Transition Metal Complexes for the Design of Innovative Phototherapeutics.Small methods · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite the advent of various medical interventions for cancer treatment, the disease continues to pose a formidable global health challenge, necessitating the development of new therapeutic approaches for more effective treatment outcomes. Photodynamic therapy (PDT), which utilizes light to activate a photosensitizer to produce cytotoxic reactive oxygen species (ROS) for eradicating cancer cells, has emerged as a promising approach for cancer treatment due to its high spatiotemporal precision and minimal invasiveness. However, the widespread clinical use of PDT faces several challenges, including the inefficient production of ROS in the hypoxic tumor microenvironment, the limited penetration depth of light in biological tissues, and the inadequate accumulation of photosensitizers at the tumor site. Over the past decade, there has been increasing interest in the utilization of photofunctional transition metal complexes as photosensitizers for PDT applications due to their intriguing photophysical and photochemical properties. This review provides an overview of the current design strategies used in the development of transition metal complexes as innovative phototherapeutics, aiming to address the limitations associated with PDT and achieve more effective treatment outcomes. The current challenges and future perspectives on the clinical translation of transition metal complexes are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.